NASDAQ:IRON Disc Medicine Q1 2025 Earnings Report $70.06 -4.08 (-5.50%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$71.05 +0.99 (+1.41%) As of 09/11/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Disc Medicine EPS ResultsActual EPS-$1.02Consensus EPS -$0.99Beat/MissMissed by -$0.03One Year Ago EPSN/ADisc Medicine Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ADisc Medicine Announcement DetailsQuarterQ1 2025Date5/7/2025TimeBefore Market OpensConference Call DateWednesday, May 7, 2025Conference Call Time8:00AM ETUpcoming EarningsDisc Medicine's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, October 30, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Disc Medicine Earnings HeadlinesWedbush Reiterates "Outperform" Rating for Disc Medicine (NASDAQ:IRON)3 hours ago | americanbankingnews.comDisc Medicine (NASDAQ:IRON) Stock Rating Upgraded by Wall Street Zen4 hours ago | americanbankingnews.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.September 12 at 1:00 AM | Investors Alley (Ad)Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONSeptember 11 at 3:11 PM | prnewswire.comDisc Medicine Reports Positive Phase 2 RESTORE-PV Data For DISC-3405 In Polycythemia VeraSeptember 10 at 7:53 AM | rttnews.comDisc Medicine Reports Positive Initial RESTORE-PV Results for DISC-3405 in Polycythemia VeraSeptember 9 at 7:31 PM | quiverquant.comQSee More Disc Medicine Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Disc Medicine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Disc Medicine and other key companies, straight to your email. Email Address About Disc MedicineDisc Medicine (NASDAQ:IRON) (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. The company’s research centers on disorders involving red blood cell production, iron metabolism and related biological pathways, with the goal of addressing conditions that often have limited treatment options. Disc Medicine’s lead product candidate is bitopertin, an oral small-molecule inhibitor of glycine transporter 1. The company is evaluating bitopertin in diseases including erythropoietic protoporphyria, a rare disorder characterized by abnormal accumulation of protoporphyrin that can cause severe sensitivity to sunlight. Its pipeline also includes DISC-0974, an investigational antibody designed to target hemojuvelin and regulate hepcidin, a hormone involved in iron metabolism, for potential use in anemia associated with chronic disease and other hematologic conditions. Founded in 2017, Disc Medicine is headquartered in Waltham, Massachusetts. The company’s programs are in clinical development and are being evaluated through studies conducted in the United States and other regions. Disc Medicine is led by John Quisel, who serves as president and chief executive officer.View Disc Medicine ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Kroger’s Textbook Entry for Buy-and-Hold InvestorsOracle’s AI Spending Is Still Huge, But the Payoff Is Starting to Show in EarningsAmgen Drops 10% on a Trial It Didn't Even RunAST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing WindowAeroVironment's Record Backlog and Earnings Beat Fuel Recovery CaseBlock Makes a Federal Trust Bank Move That Could Reshape Its Fintech ModelCould Snowflake's Big Quarter Be a Sign of More to Come? Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
